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Abstract
Background: The transglutaminase activated factor XIII (FXIIIa) acts to strengthen pathological fibrin clots and to
slow their dissolution, in part by crosslinking active a2-antiplasmin (a2AP) to fibrin. We previously reported that a
yeast-derived recombinant fusion protein comprising a2AP residues 13-42 linked to human serum albumin (HSA)
weakened in vitro clots but failed to become specifically incorporated into in vivo clots. In this study, our aims were
to improve both the stability and clot localization of the HSA fusion protein by replacing a2AP residues 13-42 with
shorter sequences recognized more effectively by FXIIIa.
Results: Expression plasmids were prepared encoding recombinant HSA with the following N-terminal 23 residue
extensions: H6NQEQVSPLTLLAG4Y (designated XL1); H6DQMMLPWAVTLG4Y (XL2); H6WQHKIDLPYNGAG4Y (XL3); and
their 17 residue non-His-tagged equivalents (XL4, XL5, and XL6). The HSA moiety of XL4- to XL6-HSA proteins was
C-terminally His-tagged. All chimerae were efficiently secreted from transformed Pichia pastoris yeast except XL3-
HSA, and following nickel chelate affinity purification were found to be intact by amino acid sequencing, as was an
N-terminally His-tagged version of a2AP(13-42)-HSA. Of the proteins tested, XL5-HSA was cross-linked to biotin
pentylamine (BPA) most rapidly by FXIIIa, and was the most effective competitor of a2AP crosslinking not only to
BPA but also to plasma fibrin clots. In the mouse ferric chloride vena cava thrombosis model, radiolabeled XL5-HSA
was retained in the clot to a greater extent than recombinant HSA. In the rabbit jugular vein stasis thrombosis
model, XL5-HSA was also retained in the clot, in a urea-insensitive manner indicative of crosslinking to fibrin, to a
greater extent than recombinant HSA.
Conclusions: Fusion protein XL5-HSA (DQMMLPWAVTLG4Y-HSAH6) was found to be more active as a substrate for
FXIIIa-mediated transamidation than seven other candidate fusion proteins in vitro. The improved stability and
reactivity of this chimeric protein was further evidenced by its incorporation into in vivo clots formed in thrombosis
models in both mice and rabbits.
Background
Recombinant serum albumins provide an attractive scaf-
fold for the delivery of attached therapeutic peptides or
proteins [1,2]. They are the most abundant proteins in
the plasma of mammals, reaching concentrations of 40-
80 mg/mL (0.6-1.0 mM) in humans [3]. They are slowly
cleared plasma proteins [3,4] whose longevity in the cir-
culation derives from a well-characterized mechanism of
recycling via the major histocompatibility complex-
related Fc receptor for immunoglobulin G (FcRn) [5-7].
Serum albumin is also unusual among plasma proteins
in that it is not glycosylated [3], a property that simpli-
fies its recombinant expression and production [8]. If
candidate therapeutic peptides or proteins can be fused
to albumin in a manner that allows them to express
their endogenous activity, the resulting fusion protein
often demonstrates improved pharmacokinetic and
pharmacodynamic properties due to acquisition of albu-
min-like circulatory characteristics [1]. For these rea-
sons, albumin has been fused to numerous proteins
such as interferon [9], interleukin-2 [10], butrylcholines-
terase [11], coagulation factors VII [12] and IX [13,14],
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peptides [18].
In order to address unmet clinical needs in the area
of thrombosis, the pathological formation of clots
within intact blood vessels, our laboratory previously
investigated novel recombinant proteins comprised of
portions of a2-antiplasmin fused to the N-terminus
of human serum albumin [19]. a2AP is cross-linked
to fibrin clots by activated factor XIII (FXIIIa), where
it promotes clot stability by inhibiting the fibrinolytic
enzyme plasmin [20,21]. We [19] and others [22,23]
have demonstrated that competing a2AP-fibrin cross-
linking results in fibrin clots that are more easily dis-
solved in vitro, suggesting potential applications of
such competitors as adjuncts to thrombolytic
therapy.
Previously, we attempted expression of three a2AP-
HSA fusion proteins in Pichia pastoris,am e t h y l o t r o -
pic yeast shown to produce recombinant HSA in high
yield and with indistinguishable biophysical properties
to its plasma-derived counterpart [24]. Our strategy
was to retain the N-terminal sites of a2AP-fibrin
crosslinking, especially Q14 [25], but to delete the C-
terminal plasmin-binding and plasmin-trapping reac-
tive centre loop of this serpin-type inhibitor. We
s o u g h tt op r o v i d ea sn a t i v eap r o t e i ne n v i r o n m e n ta s
possible for the a2AP cross-linking motif by maximiz-
ing the portion of a2AP fused to HSA. However, only
a chimeric protein comprised of a2AP residues 13-42
fused to HSA was secreted by the yeast; the two
longer fusions involving residues 13-73 and 13-109
were not stably expressed. Moreover, a2AP(13-42)-
HSA was partially proteolyzed within its a2AP moiety.
While we demonstrated that a2AP(13-42)-HSA
became a substrate of FXIIIa and competed for a2AP
crosslinking to both small and macromolecular sub-
strates, we could not demonstrate cross-linking to
clots in vivo above background levels seen with
recombinant HSA [19].
In the present study, we sought to improve the ability
of HSA fusion proteins to compete with a2AP for
FXIIIa-mediated cross-linking. The a2AP moiety was
reduced to 12 residues (a2AP 13-23 followed by
Lys24Ala), to avoid previously observed sites of proteo-
lysis by P. pastoris proteases, and compared to two 12-
residue artificial FXIIIa substrate peptides selected by
phage display for high reactivity [26]. These motifs were
expressed with or without N-terminal His tags, to allow
for purification of full length proteins away from par-
tially proteolyzed products. We hypothesized that repla-
cing a2AP 13-42 with shorter, potentially more active
FXIIIa substrate motifs would improve the stability of
fibrin cross-linkable HSA proteins and improve in vivo
clot retention.
Methods
DNA Manipulations
All oligonucleotides employed in this study were synthe-
sized at MOBIX Lab, a McMaster University core facility.
The sequences of all plasmids generated in this study were
validated by DNA sequencing, also performed by MOBIX
Lab, prior to use for protein expression. Standard molecu-
lar biological protocols for DNA restriction and ligation,
plasmid mini-DNA preparation, purification of DNA from
agarose gels, and transformation of E. coli Top10 (Invitro-
gen) to ampicillin resistance, were employed [19]. Three
plasmids encoding fusion proteins XL4-, XL5-, and XL6-
HSA were first prepared, by analogous means. Synthetic
oligonucleotides, whose sequences are shown in Table 1,
were first annealed by heating to 95°C and slow cooling to
room temperature, in pairs, for each construct, respec-
tively: ML-08-5116 and ML-08-5117; ML-08-5118 and
ML-08-5119; and ML-08-5120 and ML-ML-08-5121.
Annealed oligonucleotides were then separately ligated to
the 6325 bp XhoI-KpnI restriction digestion fragment of
previously described plasmid pPICZ9ss-a2AP(13-73)-
HSAH6 [19], replacing the a2AP(13-73) codons, forming
plasmids pPICZ9ss-XL#-HSAH6, where # corresponds to
4, 5, or 6, respectively. In order to construct XL-HSA con-
structs in which the His tag was not present on the C-ter-
minus of the HSA moiety, an intermediate construct was
prepared. A full-length preproHSA cDNA in pCDNA3.1
(Invitrogen), pC3ppHSA, was restricted with XbaI and
ApaI, and the 804 bp minor fragment was ligated to the
major 5786 bp XbaI-ApaI fragment of pPICZ9ss-a2AP
(13-73)-HSAH6, yielding plasmid pPICZ9ss-a2AP(13-73)-
HSA, in which the HSA open reading frame terminated
without hexahistidine codons. The 5768 bp XhoI-KpnI
restriction fragment of pPICZ9ss-a2AP(13-73)-HSA was
then combined with the following pair-wise annealed oli-
gonucleotides: ML-08-5104 and ML-08-5105; ML-08-
5106 and ML-08-5107; and ML-08-5108 and ML-08-5109.
This approach yielded plasmids pPICZ9ss-XL#-HSAH6,
where # corresponds to 1, 2, or 3, respectively. A final
expression plasmid was constructed to reverse the orienta-
tion of the His tag of fusion protein a2AP(13-73)-HSAH6
[19]. Plasmid pBAD-H6-a2AP [27] was PCR-amplified
using oligonucleotides ML 09-3874 and 17225 [27], and
the 125 bp XhoI-KpnI restriction fragment of the resulting
PCR product was inserted between the corresponding
sites of pPICZ9ss-a2AP(13-73)-HSA to yield pPICZ9ss-
H6a2AP(13-42)-HSA. Each completed plasmid listed
above was used to transform Pichia pastoris strain X33 to
Zeocin (Invitrogen) resistance as previously described [18].
Fusion protein expression, purification, and
characterization
HSA fusion proteins were purified from media condi-
tioned by transformed Pichia pastoris cells and induced
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[18,19,28], except that the methanol induction phase of
protein production was extended to 96 hours. At that
point, the conditioned media was neutralized and clari-
fied by centrifugation [1], treated with protease inhibitors
(5 mM benzamidine and 0.1 mM phenylmethylsulfonyl
fluoride), and purified using Ni-NTA agarose chromato-
graphy (Qiagen). Purified proteins were analyzed by SDS-
PAGE and immunoblotting using polyclonal affinity-pur-
ified goat anti-human a2AP antibodies (Affinity Biologi-
cals) and murine monoclonal anti-HSA antibodies
(Genway Biotech). They were also characterized by auto-
mated Edman degradation at the Advanced Protein
Technology Centre of the Hospital for Sick Children,
Toronto, Canada.
Transglutamination assays with biotinylated pentylamine
In order to quantify FXIIIa-catalyzed transglutamination
of plasma-derived a2AP and recombinant HSA fusion
proteins, a microtiter plate (Immulon 4 HBX, Thermo
Scientific) protocol was developed. Test HSA-related
proteins (1.7 μM) were first incubated for varying times
in Tris-buffered saline (50 mM Tris-Cl pH 7.5, 150 mM
NaCl) containing 5 mM CaCl2 and 5 mM biotinylated
pentylamine (BPA; EZ-Link pentylamine-biotin, Pierce)
supplemented with 20 nM human FXIII (Enzyme
Research Labs, ERL) and 1.0 IU/mL human thrombin
(ERL). Reactions (0.1 mL) were stopped by addition of
a ne q u a lv o l u m eo f2 0m ME D T Ap H8 . 0 0a n dt r a n s -
ferred to microtiter plates. Microtiter plates were pre-
pared for use by coating with 2.5 μg/mL mouse anti-
HSA monoclonal antibody (Genway) in 50 mM sodium
carbonate pH 9.6 overnight at 4°C. All other incubations
were at room temperature. All washes were performed
with Tris-buffered saline supplemented with 0.05% (vol/
vol) Tween 20 (TBST), and repeated three times. Anti-
HSA-coated plates were washed and then blocked for
one hour in TBST, then washed again. Following trans-
fer of the stopped transglutamination reaction mixtures
to the plate, it was incubated with shaking for one hour
and washed, prior to reaction of captured proteins with
a 1:2500 dilution of alkaline phosphatase-conjugated
streptavidin (Jackson Labs) in TBST for one hour. Fol-
lowing a final wash step, colour was developed by addi-
tion of 1.0 mg/ml p-nitrophenyl phosphate disodium
salt (PNPP) in diethanolamine buffer (1.02 M diethano-
lamine pH 9.8) (Thermo Scientific) and absorbance was
quantified on an ELx808 plater e a d e r( B i o T e kI n s t r u -
ments) at 405 nm for up to 15 minutes. In some reac-
tions, the protocol was modified to measure
Table 1 Oligonucleotides employed in this study
Oligonucleotide Size Purpose
Number Sequence (nt)
Ml-08-5104 5’-TCGAGAAAAG ACATCATCAT CATCATCATA ACCAGGAGCA GGTGTCCCCA
CTTACCCTCC TCGCTGGAGG TGGAGGGTAC-3’
80 XhoI-KpnI sense strand for XL1-HSA
ML-08-5105 5’-CCTCCACCTC CAGCGAGGAG GGTAAGTGGG GACACCTGCT CCTGGTTATG
ATGATGATGA TGATGTCTTT TC-3’
72 XhoI-KpnI antisense strand for XL1-HSA
ML-08-5106 5- TCGAGAAAAG ACATCATCAT CATCATCATG ATCAGATGAT GCTGCCATGG
CCAGCTGTGA CCCTGGGAGG CGGAGGGTAC -3’
80 XhoI-KpnI sense strand for XL2-HSA
ML-08-5107 5- CCTCCGCCTC CCAGGGTCAC AGCTGGCCAT GGCAGCATCA TCTGATCATG
ATGATGATGA TGATGTCTTT TC-3’
72 XhoI-KpnI antisense strand for XL2-HSA
ML-08-5108 5’-TCGAGAAAAG ACATCATCAT CATCATCATT GGCAGCATAA AATCGATCTG
CCATACAATG GTGCAGGAGG CGGAGGGTAC-3’
80 XhoI-KpnI sense strand for XL3-HSA
ML-08-5109 5’- CCTCCGCCTC CTGCACCATT GTATGGCAGA TCGATTTTAT GCTGCCAATG
ATGATGATGA TGATGTCTTT TC-3’
72 XhoI-KpnI antisense strand for XL3-HSA
ML-08-5116 5’- TCGAGAAAAG AAACCAGGAG CAGGTGTCCC CACTTACCCT CCTCGCTGGA
GGTGGAGGGT AC -3’
62 XhoI-KpnI sense strand for XL4-HSA
ML-08-5117 5’- CCTCCACCTC CAGCGAGGAG GGTAAGTGGG GACACCTGCT CCTGGTTTCT TTTC-3’. 54 XhoI-KpnI antisense strand for XL4-HSA
ML-08-5118 5’- TCGAGAAAAG AGATCAGATG ATGCTGCCAT GGCCAGCTGT GACCCTGGGA
GGCGGAGGGT AC -3’
62 XhoI-KpnI sense strand for XL5-HSA
ML-08-5119 5’- CCTCCGCCTC CCAGGGTCAC AGCTGGCCAT GGCAGCATCA TCTGATCTCT TTTC -3’ 54 XhoI-KpnI antisense strand for XL5-HSA
ML-08-5120 5’-TCGAGAAAAG ATGGCAGCAT AAAATCGATC TGCCATACAA TGGTGCAGGA
GGCGGAGGGT AC-3’
62 XhoI-KpnI sense strand for XL6-HSA
ML-08-5121 5’-CCTCCGCCTC CTGCACCATT GTATGGCAGA TCGATTTTAT GCTGCCATCT TTTC-3’ 54 XhoI-KpnI antisense strand for XL6-HSA
ML-09-3874 5’-ACGTGTCGAGA AAAGACATCA TCATCATCAT CATAACCAGG AGCAGGTGTC CCCAC-
3’
45 Upstream primer for PCR to assemble
H6a2AP(13-42)-HSA
ML 17225 5’-ACGTGGTACCG ACTCCTGGGG GACTCTTCAG-3’ 30 Downstream primer for PCR to assemble
H6a2AP(13-42)-HSA
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antibodies for anti-HSA antibodies, and purified human
plasma-derived a2AP (ERL) for HSA-related proteins.
Transglutamination of fibrin(ogen)
FXIIIa-catalyzed transglutamination of the natural sub-
strate fibrinogen was assessed using SDS-PAGE and
immunoblotting of cross-linking reactions as previously
described [19]. Briefly, 100 nM FXIII was first activated
to FXIIIa by reaction with 5.0 IU/ml thrombin for 5
minutes at 37°C; thrombin was then inactivated using
Phe-Pro-Arg chloromethylketone to 10 μMf i n a lc o n -
centration, to prevent clotting on addition to fibrinogen.
The resulting FXIIIa (50 nM) was reacted with 6.0 μM
human fibrinogen (specifically depleted of plasminogen,
von Willebrand factor, and fibronectin, ERL), and 1.0
μM substrate proteins in TBS containing 10 mM CaCl2.
Reactions were stopped by addition of SDS and ana-
lyzed on 8% SDS-polyacrylamide gels under reducing
conditions, with immunoblotting and chemiluminescent
development of antibody-decorated blots, as described
[19].
In vitro clot lysis
As previously described [19], the formation and dissolu-
tion of human plasma clots was followed by recording
changes in turbidity, using an ELx808 plate reader (Bio-
Tek Instruments) set to take absorbance readings at 340
nm every 30 seconds for 4 hours, and quantified as the
area under the curve.
Retention of iodinated proteins in mouse vena cava
treated with ferric chloride
Purified human fibrinogen (Sigma), human a2AP (ERL),
or XL5-HSA recombinant proteins were iodinated using
the Iodogen method as described by the manufacturer
(Pierce), using either sodium
125Io r
131I. Unincorpo-
rated radioactivity was removed by exhaustive dialysis
versus phosphate-buffered saline. Specific activities of
labelling exceeded 1 × 10
9 cpm/mg. Radioiodinated pro-
teins were then tested in the mouse ferric chloride vena
cava thrombosis model, modified from [29,30]. CD-1
mice were anaesthetized using gaseous anaesthesia (3%
isofluorane) at all times during this procedure, and a
heating pad was employed to ensure maintenance of
normal body temperature. A mid-line incision was
made, first through the skin and secondly through the
muscle layer. Viscera were gently displaced and haemo-
static clamps employed to keep the incision open. At
this time radioiodinated proteins (5 × 10
6 cpm in 0.1 ml
sterile saline) were injected via the tail vein. The vena
cava was then exposed and a 2 × 4 mm piece of What-
man paper soaked in 10% (w/vol) ferric chloride was
applied. The viscera were covered with gauze soaked in
warm saline during this time. The time from radioactive
protein injection to application of ferric chloride was
fixed at 5 minutes. Three minutes after its application,
the filter paper was removed and viscera replaced.
Thirty minutes later, the vena cava was re-exposed, the
vessel was excised, and the clot was transferred to a
tared tube for weighing, and then subjected to g count-
ing using either an Auto Gamma 5530 Minaxi g counter
(Perkin Elmer) or a Cobra II g counter (Packard) to
quantify incorporated radioactivity.
Retention of iodinated proteins in rabbit jugular vein
thrombi
New Zealand White rabbits were subjected to a modi-
fied Wessler procedure [31] as previously described by
this laboratory [19]. Briefly, animals were initially
anesthetized with 100 mg of ketamine, then maintained
in the anesthetized state with 1.5% isoflurane. They
were then cannulated via the carotid artery and the
jugular veins isolated. One ml of whole blood was
freshly drawn and anticoagulated with 1/9
th volume of
3.8% w/vol sodium citrate. Two centimeter long sections
of the right and left jugular veins were isolated, emptied
of blood, and isolated using bulldog clamps. Clotting of
the anticoagulated, autologous whole blood was initiated
by combining it with warm (37°) human thromboplastin
reagent Thromborel S (Dade Behring) in a 1:4 (vol:vol)
ratio, supplementing it to 3.3 × 10
6 cpm/ml
131I- fibri-
nogen and
125I-recombinant protein, and re-introducing
0.15 ml of the clotting blood into the isolated segments.
This was done for both isolated jugular veins and blood
flow was held in stasis for 30 minutes, at which time the
clamps were removed, and blood flow restored. Clots
were recovered 60 minutes later, following jugular vein
opening by incision, and removed, weighed, and g-
counted as described above for murine clots. In some
experiments clots were extracted overnight in 5.0 M
urea, microcentrifuged, and the supernatant removed
prior to re-counting. The proportion of urea-stable pro-
tein incorporation was then calculated, adjusted for
radioactive decay between the recorded times of the first
and second g-count. All animal experiments were car-
ried out under the terms of an approved Animal Utiliza-
tion Protocol reviewed, approved, and monitored by the
Animal Research Ethics Board of the Faculty of Health
Sciences, McMaster University.
Statistical analysis
Statistical tests were performed using GraphPad Instat
version 4 (GraphPad Software). Multiple comparisons
used one-way parametric analysis of variation (ANOVA)
with Tukey-Kramer post-tests where data were normally
distributed, and nonparametic ANOVA with Dunn’s
post-tests where they were not.
Sheffield and Eltringham-Smith BMC Biotechnology 2011, 11:127
http://www.biomedcentral.com/1472-6750/11/127
Page 4 of 14Results
Expression and characterization of fusion proteins
Media conditioned by Pichia pastoris cultures trans-
formed with expression plasmids encoding fusion pro-
teins XL(1-6)-HSA (see Figure 1) were first screened for
recombinant expression of HSA-related polypeptides by
gel analysis. As shown in Figure 2A, although there
were some differences in the time course of expression,
five of six of the yeast cell lines secreted a major metha-
nol-dependent polypeptide of the expected size of the
HSA fusion proteins, of 70-80 kDa. The exception was
the cell line programmed toe x p r e s sX L 3 - H S A ,w h i c h
secreted no detectable methanol-dependent
polypeptides.
The five putative HSA fusion proteins were purified
from conditioned media induced with methanol for 96
hours, using nickel chelate affinity chromatography, and
reacted both with anti-HSA and anti-hexahistidine anti-
bodies, as shown in Figure 2B. The same properties
were observed for H6a2AP(13-42)-HSA and previously
described a2AP(13-42)-HSA [19] (Figure 2). Similar
results were obtained when an additional two
Figure 1 HSA fusion protein design, expression, and characterization. (A) Schematic diagram of proteins. Relevant polypeptides are shown
in linear form, oriented from N-terminus to C-terminus, with different regions labelled on the bar diagram. HSA residues are shown in black,
while candidate FXIIIa substrate motifs are shown in grey. White bars correspond either to hexahistidine tags (H6) or to tetraglycine-tyrosyl
spacer segments (G4Y). Polypeptide names and predicted length in amino acids (a.a.) is shown at right. (B) Amino acid sequence of candidate
FXIIIa substrate motifs. The amino-terminal portion of a2AP previously fused to HSA [19] is shown, including putative sites of proteolysis
deduced by amino acid sequencing, on the top line (a2AP(13-42)). The three candidate FXIIIa motifs fused to albumin with or without adjacent
His tags, are shown below (XL1,2, or 3).
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Page 5 of 14Figure 2 Expression, purification and characterization of HSA-related recombinant proteins. (A) Electrophoresis of conditioned media
from P. pastoris transformed with different expression plasmids. Conditioned media samples taken 24, 48, 72, or 96 hours after the start of
methanol induction are shown on 10% reducing SDS-polyacrylamide gels stained with Coomassie Blue. The protein product encoded by the
expression plasmid is shown above each gel. The position of molecular mass markers (200, 150, 120,. 100, 85, 70, 60, 50, 40, and 30 kDa) is
shown to the left of each panel and labelled (XL4-HSA) in one instance as an example. (B) Upper panel, gel profile of purified recombinant
proteins on 10% SDS-polyacrylamide gels electrophoresed under reducing conditions and stained with Coomassie Blue. Proteins (400 ng) are
identified above each lane as in Figure 1A, plus GST (E.coli-expressed glutathione sulfotransferase); M, molecular mass markers identical to those
used in Figure 1A. Middle and lower panel, replicate gels differing only in the amounts of protein loaded per lane, to avoid overloading with
antibodies of different affinity, were immunoblotted and probed with Anti-HSA antibodies (middle pane, 100 ng/lane) or anti-hexahistidine
antibodies (lower panel, Anti-His, 500 ng/lane).
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e x a m i n e d ,i na d d i t i o nt ot h eo n e ss h o w ni nF i g u r e2
(data not shown).
Because the minor, 2-4 kDa difference between the
shortest (HSAH6) and longest (H6a2AP(13-42)-HSA)
putative expression proteins was not resolvable on the
gel system we employed, we sought independent confir-
mation of the identity and integrity of the expressed
protein products by amino acid sequencing. For XL(4-
6)-HSA, a single N-terminal sequence was detected by
Edman degradation: NQEQVS; DQMMLP; and
WQHKID, respectively. For XL1-HSA and XL2-HSA,
Edman degradation showed intact hexahistidine amino-
termini. For H6a2AP(13-42)-HSA, two sequences were
detected: the major sequence arising from the expected
hexahistidine tag, and the other a mixture of amino
acids suggestive of a similar pattern of partial proteolysis
we previously reported for a2AP(13-42)-HSA [19]. In
that regard, batches of the latter protein were prepared
using 96 hours of methanol induction, as employed for
all other proteins in this study, for consistency and for
comparative purposes. Edman degradation showed a
mixture of termini similar to those previously observed
from cultures induced for lesser periods of time [19].
These included termini commencing with Leu23
(LKLGNQ), Leu25 (LGNQEP), and Ser38 (SPPGVC)
but no detectable full-length product. Three separate
batches of such protein preparations returned similar
results (data not shown).
While the amino acid sequencing results showed that
positioning of a hexahistidine tag on the N-terminus of
a2AP(13-42)-HSA improved the integrity of the result-
ing purified protein product, the yield was reduced from
40-50 mg/l for AP(13-42)-HSA to 5-6 mg/l for H6a2AP
(13-42)-HSA. Yields for the purified XL-HSA proteins
varied from 10-12 mg/l (XL1- and XL2-HSA) to 20-35
mg/l ( XL4- and XL5-HSA) to 80-85 mg/l (XL6-HSA).
Characterization of recombinant fusion proteins as fXIIIa
substrates for cross-linking to lysine donors
Having demonstrated that all recombinant fusion pro-
teins with the exception of XL3-HSA had been pro-
duced, we next asked whether the addition of the
candidate FXIIIa sequences had actually converted the
proteins into substrates for cross-linking by FXIIIa.
Cross-linking reactions were performed in solution,
using the chemical amine donor biotinylated pentyla-
mine, and reaction products were captured using anti-
bodies immobilized on microtiter plate walls and
quantified colorimetrically using alkaline-phosphatase-
linked streptavidin. As shown in Figure 3A, while there
was evidence of some cross-linking for all proteins
tested, the highest levels were observed for fusion pro-
teins XL5-HSA and XL2-HSA, in that order. While the
Figure 3 FXIIIa-mediated cross-linking of recombinant proteins
and plasma-derived a2AP to biotinylated pentylamine. Panel A
shows transglutamination reactions, in which 20 nM FXIIIa cross-
linked 5 mM BPA to 1.7 μM HSA fusion proteins (identified below
the × axis), were stopped after 2.5 minutes and the relative BPA
incorporation was quantified using anti-HSA capture and alkaline
phosphatase-conjugated streptavidin detection as outlined in
“Methods”. Colour generation was quantified as the optical density
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minute) reactions, by five minutes the cross-linking of
XL2-HSA and XL5-HSA had become comparable (data
not shown).
Similar results were obtained when HSA fusion pro-
teins were employed as competitors of the FXIIIa-
dependent transfer of biotin from BPA to a2AP, which
exhibited time-dependent crosslinking on the time scale
employed (see Figure 3B). As shown in Figure 3C, of
seven proteins tested using a seven-fold excess of com-
petitor over a2A P ,o n l yX L 5 - H S A ,X L 2 - H S A ,a n d
H6a2AP(13-42)-HSA significantly reduced cross-linking
of a2AP; the relative efficacy of the proteins was in the
order listed. To minimize the possibility that reactivity
with BPA was an artefact that did not accurately predict
reactivity with macromolecular donors, the ability of
XL5-HSA to be cross-linked to fibrinogen was tested.
As shown in Figure 4, XL5-HSA and a2AP exhibited
similar kinetics in forming high molecular weight
products with fibrinogen that were dependent on added
FXIIIa, although the fact that different antibodies, with
potentially different binding efficiency, had to be
employed limited the comparison to a qualitative assess-
ment. A similar pattern was observed for both proteins
in that three higher molecular weight bands of 140 kDa
and greater formed in a factor XIIIa- and fibrinogen-
dependent manner; with respect to plasma-derived
a2AP, these bands have been suggested to represent
a2AP-fibrinogen Aa chain, a2AP-fibrinogen Aa dimer,
and a2AP-fibrinogen Aa polymers [32].
Comparison of fusion proteins as competitors of a2AP-
mediated in vitro clot protection
a2AP attenuates the ability of tPA to lyse fibrin clots by
inhibiting plasmin generated by tPA-mediated activation
of plasminogen. This property can be demonstrated in
vitro using a2AP-deficient plasma. As shown in Figure
5A, clots formed in the absence of tPA and a2AP were
stable for > 4 hours, whereas the addition of tPA lead to
complete lysis within 60 minutes. Restoration of a2AP
to its physiological concentration of 1 μMr e s t o r e d
a p p r o x i m a t e l y7 0 %o ft h ea r e au n d e rt h et u r b i d i t y
curve. The ability of the HSA-related fusion proteins to
compete for the a2AP-mediated lysis attenuation was
tested by addition of 20 μM fusion proteins. Although
at this excess, some changes in the shape of the turbid-
ity plot in the presence of fusion protein and the
absence of fusion protein could be noted (Figure 5A),
the area under the curve (AUC) of the turbidity curve
did not differ from baseline, as exemplified for XL5-
HSA and XL6-HSA in Figure 5B. XL5-HSA significantly
reduced the a2AP-mediated attenuation of clot lysis,
at 405 nm (OD (405 nm)). The mean ± standard deviation (SD) of 6
determinations is shown, with background (reactions lacking FXIIIa)
subtracted. Panel B shows a time course of FXIIIa-mediated cross-
linking of BPA to 1.7 μM a2AP, using the same conditions as
employed in Panel A except that anti-a2AP antibodies were used to
capture biotinylated a2AP after reaction termination at various time
points. The mean ± the standard deviation (SD) of 3 determinations
is shown, with background (reactions lacking FXIIIa) subtracted.
Panel C shows BPA-a2AP crosslinking reactions of 5 minutes’
duration, as shown in panel B, except that competitor proteins
identified on the × axis were included at 12 μM. The mean ± the
SD of 5-14 determinations is shown, with background (reactions
lacking FXIIIa) subtracted.
Figure 4 FXIIIa-mediated cross-linking of a2AP and XL5-HSA to fibrinogen. FXIII was pre-activated to fXIIIa by thrombin, the thrombin
inactivated with FPRck, and the fXIIIa then combined with fibrinogen and a2AP (A) or XL5-HSA (B) in transglutamination reactions probed, after
reducing SDS-polyacrylamide electrophoresis, with either (A) anti-a2AP or (B) anti-HSA antibodies. The position of pre-stained molecular mass
markers is indicated to the left of the panels. Reactions containing only FXIII, only fibrinogen, or only a2AP are also shown.
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Page 8 of 14Figure 5 Effects of a2AP and recombinant HSA-related proteins on plasma clot formation and lysis. Clot formation and lysis were
followed by monitoring turbidity (absorbance at 340 nm) every 30 seconds for 4 hours using a plate reader, of clots formed using diluted a2AP-
deficient plasma, recalcified with 5 mM CaCl2 and supplemented with both 5 nM thrombin and 0.125 nM tPA, and taking the area under the
turbidity versus time curve (AUC). Reactions were carried out with or without addition of 1 μM a2AP and/or 20 μM fusion protein. (A) shows
results of a single representative experiment. (B) shows quantification of turbidity plots for reactions similar to those shown in A, in the presence
or absence of XL5-HSA or XL6-HSA competitor proteins; reaction components are indicated (+ or -) below the graph. The mean ± SD of 5-14
determinations is shown. AUC values were normalized, taking the no tPA, no a2AP condition as 100% (grey bar); white (open) bars correspond
to tPA only condition. (C) shows similar results to panel B for additional competitor proteins identified below the graph. As in panel B, the mean
± SD of 5-14 determinations is shown.
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Page 9 of 14shifting the AUC from 70.8 ± 14% of maximal clotting
to 40.5 ± 2.9% (Figure 5B); in contrast XL6-HSA did
not compete for the a2AP effect. Extension of these
comparisons to the complete set of recombinant fusion
proteins showed that only XL5-HSA and H6a2AP(13-
42)-HSA, under the conditions employed, reduced the
a2AP effect, and that only the XL5-HSA reduction was
statistically significant.
Fusion protein XL5-HSA is retained in experimental
thrombi in mice and rabbits
Having obtained several lines of evidence that fusion
protein XL5-HSA was the most effective FXIIIa sub-
strate of the recombinant proteins tested, we next asked
whether, like a2AP, it was capable of being retained
within whole blood clots in vivo.A ss h o w ni nF i g u r e
6A, when equal doses of radiolabeled a2AP, XL5-HSA,
and HSAH6 were injected into mice that formed experi-
mental thrombi in the vena cava d u et of e r r i cc h l o r i d e
administration, both a2AP and XL5-HSA were retained
within clots to a significantly greater extent than
HSAH6.T h er e t e n t i o no fa2A Po nac l o tw e i g h tb a s i s ,
was also significantly greater than that of XL5-HSA.
Similar results were obtained using a larger, rabbit
experimental model in which the radiolabeled proteins
were introduced, with a coagulation activator, into a
whole blood segment within the isolated rabbit jugular
vein. As shown in Figure 6B, the three proteins were
found to become incorporated into the clot with the
same relative efficacy as in the murine model; both
a2AP and XL5-HSA were incorporated to a greater
extent than HSAH6.H o w e v e r ,i nc o m m o nw i t ht h e
murine results, the XL5-HSA tracer incorporation was
significantly less than that of a2AP.
Fusion protein XL5-HSA is retained in a urea-sensitive
manner in experimental thrombi in rabbits
In the larger animal model, the rabbit, the greater physi-
cal size of the clot permitted its manipulation, unlike
with the much smaller murine thrombi. Prolonged stasis
and the direct introduction of tissue factor activator into
the isolated vessel strongly favoured thrombus formation
in the rabbit model, as compared to the localized appli-
cation of indirectly procoagulant ferric chloride to a
localized area of a much smaller vessel in the mouse.
Accordingly, clot weights from rabbits ranged from 21.4
to 54.1 mg versus 5.1 to 11.4 mg in mice. This greater
size permitted clot extraction in 5.0 M urea and deter-
mination of the fraction of clot-bound radioactivity that
was insensitive to urea, a hallmark of cross-linked pro-
tein clot incorporation. In these experiments, the three
125I-labeled proteins were each separately co-adminis-
tered with
131I-labeled fibrinogen. As shown in Figure
7A, approximately 50% of injected fibrinogen was clot-
associated in a urea-insensitive manner; there were no
differences between treatment groups, as expected
because tracer-level doses of the recombinant proteins
were employed. While significantly greater amounts of
a2AP remained clot-bound after urea extraction than
XL5-HSA (15.8 ± 2.8% of injected dose versus 7.52 ±
1.7%) (Figure 7B), this represented 15- and 7.5-fold
greater urea-insensitive retention than for HSAH6 (1.00
± 0.43%).
Discussion
In this study, we sought to increase the stability and
activity of HSA fusion proteins containing short N-
terminal extensions that are substrates for transglutami-
nation by FXIIIa. Our long-term goal was to produce
well-tolerated therapeutic proteins for injection, with the
long circulatory half-life of albumin, and the ability to
compete the cross-linking of a2AP to fibrin in thrombi.
Replacing active a2AP in the clot with a protein incap-
able of inhibiting plasmin could render pathological
clots easier to dissolve. Others have suggested that che-
mically or mutationally inactivated a2AP could serve
this purpose [22,23], while we have focused on the albu-
min fusion strategy [19], due to the ease of large-scale
production of recombinant albumin [8]. In this study,
we built chimeric albumin fusion proteins modelled on
a2AP(13-42)-HSA, seeking to eliminate the partial pro-
teolysis of this prototype, but retain and enhance its
ability to be cross-linked by FXIIIa. Our approaches
included shortening the natural a2AP-derived cross-
linking site, replacing it with either of two FXIIIa highly
active substrate sequences identified by phage display,
and capping all three novel chimerae with hexahistidine
tags.
Substituting the sequence DQMMLPWPAVTL for
a2AP(13-42), in fusion protein XL5-HSA, was found to
be the most effective approach. This sequence had been
r e p o r t e dt ob eah i g h l yf a v o u r a b l es u b s t r a t ef o rF X I I I a -
mediated transglutamination, when expressed fused to a
phage coat protein or to glutathione sulfotransferase
(GST) (designated F11 in [26]). When expressed fused
to HSA, it yielded the candidate protein most rapidly
and efficiently cross-linked to BPA, and the most effec-
tive competitor of a2AP crosslinking, both with small
substrates and in competition of a2AP’s in vitro antifi-
brinolytic effect. The molecular context of the fusion
partner was relevant, since sequence WQHKIDL-
PYNGA, identical to sequence F28 in [26], except for
substitution of protease-susceptible R for P at position
8, appeared to be much less active in fusion protein
XL6-HSA than in the GST context. Similarly, a2AP(13-
23)K24A, although shown to be effectively crosslinked
by FXIIIa as a2AP(13-23) or a2AP(13-24) free peptides
[33-35], was ineffective at competing a2AP crosslinking
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Page 10 of 14Figure 6 Retention of radiolabeled proteins in experimental thrombi formed in mice or rabbits. (A) The radioactivity remaining in clots
induced by surgical, topical application of 10% ferric chloride to the vena cava of anesthetized mice is shown, as a fraction of the total
radioactive protein dose injected, divided by the weight of the clot. Injected radiolabeled proteins are identified on the × axis. The mean ± SD
of 12 determinations is shown. (B) The radioactivity remaining in rabbit jugular vein clots formed in clamped-off vessels in situ for 30 minutes in
the anesthetized animal, then exposed to circulating blood for 60 minutes, prior to clot recovery and g-counting is shown, expressed as in
Figure 6A. The extent (p < 0.001, p < 0.05) of statistical significance is shown for the data sets linked by horizontal lines.
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Page 11 of 14Figure 7 Retention of radiolabeled proteins in experimental thrombi formed in rabbits following extraction in 5.0 M urea. Rabbits were
co-injected with
131I-fibrinogen and
125I-proteins identified in Figure 6 and jugular vein clots were formed as described in “Methods” Clots were
g-counted at the close of the experiment, and then extracted overnight with 5.0 M urea, the supernatant aspirated, and the clots recounted. The
fraction of the total injected radiolabeled protein dose found in the clot after urea extraction is shown for
131I-fibrinogen, identified by the co-
injected
125I protein on the × axis in (A) and for
125I-labeled proteins in (B). Differences between
131I-fibrinogen among the three groups in (A)
are not statistically significant; the extent of statistically significant differences between groups is shown for the data sets linked by horizontal
lines in (B). The mean ± SD of 12 determinations is shown.
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Page 12 of 14to fibrin in fusion protein XL4-HSA. Although our
avoidance of Lys or Arg residues in the fusion motifs
was successful in avoiding degradation in each case,
only XL5-HSA was clearly superior not only to XL4-
HSA or XL6-HSA but also to a2AP(13-42)-HSA.
Although the requirements for optimal substrates of
FXIIIa have not been precisely defined, they are thought
to involve positioning of a reactive glutamine residue
w i t h i nah i g h l yf l e x i b l es e q u e n c e[ 3 6 ] .F u s i o np r o t e i n s
XL4-, XL5-, and XL6-HSA all contained a reactive gluta-
mine at position 2, analogous to Q14, the most reactive
glutamine in the native a2AP sequence. Q14 is more
effectively cross-linked by FXIIIa in the major form of
a2AP that circulates in plasma, Asn-a2A P ,t h a ni nt h e
minor precursor form, Met-a2AP, which retains residues
1-12 [37]. Our finding that positioning a hexahistidine
tag N-terminal to the FXIIIa substrate motif reduced its
activity in fusion proteins XL1- and XL2-HSA was con-
sistent both with this natural example and with the gen-
eral concept of flexibility of the reactive glutamine.
Previously, we found that a2AP(13-42)-HSA was no
more likely to be present in vivo in the rabbit jugular vein
model of thrombosis than recombinant HSA [19]. In con-
trast, XL5-HSA was retained in thrombi in vivo to a signif-
icantly greater extent than recombinant HSA in both
rabbit and murine models. Its degree of retention was less
than that of human a2AP in both cases, suggesting that
there is still room for improvement in defining an optimal
sequence to render HSA efficiently cross-linked by factor
XIIIa. Nevertheless, this is the first demonstration of tar-
geting of an inactive carrier protein to in vivo clots by an
attached transamidation substrate motif, although, as
described below, others have shown in vivo clot associa-
tion of transamidation substrate motif peptides [35] and
peptide-contrast agent conjugates [33,34]
The insolubility of cross-linked fibrin in 5.0 M urea is
a property that has been known for many years, and
indeed is used clinically to diagnose FXIII deficiency
[38]. Using this property, we showed that in vivo clot-
associated XL5-HSA is urea-insoluble, like the majority
of bound fibrin or a2AP, but unlike the majority of
bound HSA. Although much indirect or in vitro evi-
dence supports the importance of a2AP cross-linking to
fibrin with respect to clot resistance to fibrinolysis
[22,23,39,40], this is to our knowledge the first demon-
stration of cross-linking of either a2AP protein or an
engineered polypeptide into in vivo thrombi. Other
groups have used peptides in this regard, but predomi-
nantly in an analytical or imaging mode distinct from
long-term goal of reducing thrombus size using cross-
linkable proteins. Robinson et al. showed that biotiny-
lated a2AP (13-24) peptide became cross-linked to
human thrombi embolized into the lungs of ferrets and
mice when infused in vivo [35]. Jaffer et al. employed an
a2AP (13-24) peptide linked to a near infrared fluoro-
chrome to image murine thrombi formed following fer-
ric chloride treatment of the femoral vessels [34], while
Miserus et al., used a similar a2AP (13-23) peptide con-
jugated to a gadolinium-containing contrast agent to
visualize murine carotid artery ferric chloride-induced
thrombi [33]. While these peptides and peptide-chemi-
cal conjugates show great promise for future improved
detection of thrombi and stratification of patients, pep-
tides are typically cleared from the circulation with
extremely rapid pharmacokinetics. That fusion protein
XL5-HSA was found to localize in in vivo thrombi to a
greater extent than unmodified recombinant HSA sug-
gests not only its superiority over our previously
described a2AP (13-42)-HSA chimera, but also its
potential utility in being incorporated as a “Trojan
horse” into thrombi, and making them more susceptible
to natural or pharmacological thrombolysis.
Conclusions
Recombinant HSA with a DQMMLPWPAVTLG4YN -
terminal extension (XL5-HSA) was more active as a sub-
strate for FXIIIa-mediated cross-linking to either artificial
or natural transglutamination partners than other candi-
date motifs of identical or longer length, with or without
an N-terminal His tag. XL5-HSA, unlike a2AP(13-42)-
HSA or H6a2AP(13-42)-HSA, was not subject to detect-
able proteolysis by P. pastoris. Of the proteins tested, XL5-
HSA was the most effective competitor of a2AP-mediated
resistance of fibrin clots to lysis. In contrast to previous
results with a2AP(13-42)-HSA, radiolabeled tracer XL5-
HSA was found to a greater extent in experimentally-
induced intravascular clots in both murine and rabbit in
vivo venous thrombosis models; importantly, the majority
of clot-associated XL5-HSA and plasma-derived a2AP,
but not recombinant HSA, was shown to be insoluble to
5.0 M urea, suggesting covalent cross-linking. Our results
suggest that fusion protein XL5-HSA has been sufficiently
optimized over prototype a2AP(13-42)-HSA to warrant in
vivo testing as a potential protein drug rendering thrombi
more susceptible to natural or pharmacological clot lysis.
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